TABLE 1 BASELINE CHARACTERISTICS FOR THE CO-AMOXICLAV GROUP

	Total (N=118)	Co-Amoxiclav				
		Consented to swabs (N=103)	Swabs available at 3 months (N=55)	Swabs available at 6 months (N=47)	Swabs available at 12 months (N=47)	Swabs available at 3 6 and 12 months (N=34)
Age (months)						
Median (IQR)	42.5 (20.0 to 89.6)	42.0 (20.9 to 86.6)	41.7 (20.9 to 89.6)	37.7 (20.9 to 86.6)	33.0 (20.9 to 89.6)	36.7 (20.9 to 92.1)
Age						
6-23 months, n(%)	39 (33%)	33 (32%)	20 (36%)	16 (34%)	18 (38%)	14 (41%)
≥2 years, n(%)	79 (67%)	70 (68%)	35 (64%)	31 (66%)	29 (62%)	20 (59%)
Age category (by EduraCT guidelines)						
Infants (28 days-23 months), n(%)	39 (33%)	33 (32%)	20 (36%)	16 (34%)	18 (38%)	14 (41%)
Children (2-11 years), n(%)	77 (65%)	68 (66%)	34 (62%)	30 (64%)	28 (60%)	19 (56%)
Adolescents (12-17 years), n(%)	2 (2%)	2 (2%)	1 (2%)	1 (2%)	1 (2%)	1 (3%)
Gender						
Male, n(%)	73 (62%)	65 (63%)	38 (69%)	31 (66%)	31 (66%)	22 (64%)
Female, n(%)	45 (38%)	38 (37%)	17 (31%)	16 (34%)	16 (34%)	12 (35%)
Region[1]						
A, n(%)	41 (35%)	41 (40%)	30 (55%)	28 (60%)	29 (62%)	21 (62%)
B, n(%)	29 (25%)	23 (22%)	7 (13%)	5 (11%)	4 (9%)	2 (6%)
C, n(%)	19 (16%)	15 (15%)	7 (13%)	6 (13%)	6 (13%)	6 (18%)
D, n(%)	19 (16%)	17 (17%)	5 (9%)	4 (9%)	2 (4%)	1 (3%)
E, n(%)	10 (8%)	7 (7%)	6 (11%)	4 (9%)	6 (13%)	4 (12%)
Current season influenza vaccination						
Yes, n(%)	37 (31%)	31 (30%)	20 (36%)	15 (32%)	18 (38%)	12 (35%)
No, n(%)	79 (67%)	71 (69%)	35 (64%)	32 (68%)	29 (62%)	22 (65%)
Don't know, n(%)	2 (2%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Last year seasonal influenza vaccination						
Yes, n(%)	40 (34%)	33 (32%)	19 (35%)	17 (36%)	17 (36%)	14 (41%)
No, n(%)	56 (47%)	49 (48%)	27 (49%)	24 (51%)	21 (45%)	17 (50%)
Don't know, n(%)	22 (18%)	21 (20%)	9 (16%)	6 (13%)	9 (19%)	3 (9%)

	Total (N=118)		Consented to swabs (N=103)		Co-Amoxiclav Swabs available at 3 months (N=55)		Swabs available at 6 months (N=47)		Swabs available at 12 months (N=47)		Swabs available at 3 6 and 12 months (N=34)	
Household smoking status												
Non-smoking, n(%)		100 (85%)		88 (85%)		50 (91%)		43 (91%)		42 (89%)		31 (91%)
Smoking, n(%)		16 (14%)		14 (14%)		4 (7%)		4 (9%)		4 (9%)		8 (9%)
Missing, n(%)		2 (2%)		1 (1%)		1 (02%)		0 (0%)		1 (2%)		0 (0%)
At risk categories (not mutually exclusive)												
Respiratory, n(%)		85 (72%)		76 (74%)		43 (78%)		38 (81%)		37 (78%)		29 (85%)
Neurological, n(%)		6 (5%)		5 (5%)		2 (4%)		2 (4%)		1 (2%)		1 (3%)
Cardiac, n(%)		12 (10%)		9 (9%)		5 (9%)		2 (4%)		2 (2%)		0 (0%)
Renal, n(%)		3 (3%)		3 (3%)		1 (2%)		2 (4%)		1 (2%)		1 (3%)
Immunodeficiency, n(%)		1 (1%)		1 (1%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)
Other, n(%)		26 (22%)		20 (19%)		11 (20%)		8 (17%)		11 (23%)		6 (18%)
- Genetic, n(%)		*7 (27%)*		*5 (25%)*		*4 (36%)*		*1 (13%)*		*4 (36%)*		*1 (17%)*
- Metabolic, n(%)		*1 (4%)*		*1 (5%)*		*0 (0%)*		*1 (13%)*		*0 (0%)*		*0 (0%)*
- Premature birth, n(%)		*11 (42%)*		*10 (50%)*		*5 (45%)*		*4 (50%)*		*5 (45%)*		*4 (67%)*
- Previous recurrent or serious respiratory problems, n(%)		*5 (19%)*		*2 (10%)*		*2 (18%)*		*2 (25%)*		*1 (9%)*		*1 (17%)*
- Other (allergies, etc.)		*2 (8%)*		*2 (10%)*		*0 (0%)*		*0 (0%)*		*1 (9%)*		*0 (0%)*
Physical examination, n mean (SD)												
Heart rate (beats/minute)	116	114 (22.9)	101	114 (22.9)	54	116 (22.9)	46	115 (21.6)	46	114 (23.4)	33	115 (23.6)
Respiratory rate (breaths/minute)	117	27 (8.8)	102	27 (8.4)	55	27 (8.2)	47	27 (8.7)	47	27 (8.7)	34	28 (9.0)
Temperature (°C)	118	37 (0.8)	103	37 (0.8)	55	37 (0.8)	47	37 (0.8)	47	37 (0.8)	34	37 (0.8)
Antibiotics prescribed in the 3 months preceding randomisation												
Yes, n(%)		28 (24%)		19 (18%)		11 (20%)		10 (21%)		10 (21%)		8 (24%)
No, n(%)		83 (70%)		77 (75%)		41 (75%)		34 (72%)		35 (74%)		24 (71%)
Not known, n(%)		5 (4%)		5 (5%)		2 (4%)		2 (4%)		2 (4%)		2 (6%)
Missing, n(%)		2 (2%)		2 (2%)		1 (2%)		1 (2%)		0 (0%)		0 (0%)
Medication taken during current episode:												
Antivirals												
Yes, n(%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)
No, n(%)		115 (97%)		100 (97%)		53 (96%)		46 (98%)		46 (98%)		33 (97%)
Unknown, n(%)		2 (2%)		2 (2%)		1 (2%)		0 (0%)		0 (0%)		0 (0%)
Missing, n(%)		1 (1%)		1 (1%)		1 (2%)		1 (2%)		1 (2%)		1 (3%)

	Total (N=118)	Consented to swabs (N=103)	Co-Amoxiclav Swabs available at 3 months (N=55)	Swabs available at 6 months (N=47)	Swabs available at 12 months (N=47)	Swabs available at 3 6 and 12 months (N=34)
Antipyretics						
Yes, n(%)	99 (84%)	86 (84%)	47 (85%)	44 (94%)	41 (87%)	31 (91%)
No, n(%)	17 (15%)	15 (15%)	7 (13%)	2 (4%)	5 (11%)	2 (6%)
Unknown, n(%)	2 (2%)	2 (2%)	1 (2%)	1 (2%)	1 (2%)	1 (3%)
Other medications						
Yes, n(%)	67 (57%)	57 (55%)	32 (58%)	29 (62%)	30 (64%)	23 (68%)
No, n(%)	50 (42%)	45 (44%)	23 (42%)	18 (38%)	17 (36%)	11 (32%)
Not known, n(%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	
Hib vaccination status						
Yes, n(%)	108 (92%)	95 (92%)	51 (93%)	43 (91%)	44 (94%)	31 (91%)
No, n(%)	7 (6%)	5 (5%)	3 (5%)	3 (6%)	3 (6%)	3 (9%)
Not known, n(%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Missing, n(%)	2 (2%)	2 (2%)	1 (2%)	1 (2%)	0 (0%)	0 (0%)
PCV vaccination received						
Yes, n(%)	107 (91%)	92 (89%)	49 (89%)	42 (89%)	45 (96%)	32 (94%)
No, n(%)	8 (7%)	8 (8%)	5 (9%)	4 (9%)	2 (4%)	2 (6%)
Not known, n(%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Missing, (%)	2 (2%)	2 (2%)	1 (2%)	1 (2%)	0 (0%)	0 (0%)
Any acute consultations in the 12 month period before entering the study						
Yes, n(%)	106 (90%)	92 (89%)	48 (87%)	41 (9%)	41 (87%)	29 (85%)
No, n(%)	8 (7%)	7 (7%)	5 (9%)	4 (9%)	5 (11%)	4 (12%)
Not known, n(%)	2 (2%)	2 (2%)	1 (2%)	1 (2%)	1 (2%)	1 (3%)
Missing, n(%)	2 (2%)	2 (2%)	1 (2%)	1 (2%)	0 (0%)	0 (0%)
Total number of acute consultations in the 12 month period before entering the study						
N	85	74	37	34	32	24
Median (IQR)	5.0 (3.0 to 10.0)	5.0 (3.0 to 9.0)	5.0 (3.0 to 9.0)	4.0 (2.0 to 9.0)	4.0 (2.0 to 9.0)	4.5 (2.5 to 9.5)

	Total (N=118)	Consented to swabs (N=103)	Co-Amoxiclav Swabs available at 3 months (N=55)	Swabs available at 6 months (N=47)	Swabs available at 12 months (N=47)	Swabs available at 3 6 and 12 months (N=34)
Influenza						
Any Influenza strain, n(%)	19 (16%)	18 (17%)	10 (18%)	9 (19%)	9 (19%)	7 (21%)
- Influenza A, n(%)	*3 (3%)*	*3 (3%)*	*2 (4%)*	*2 (4%))*	*2 (4%)*	*2 (6%)*
- Influenza A/H1, n(%)	*0 (0%)*	*0 (0%)*	*0 (0%)*	*0 (0%)*	*0 (0%)*	*0 (0%)*
- Influenza A/H1-2009, n(%)	*1 (1%)*	*1 (1%)*	*1 (2%)*	*0 (0%)*	*0 (0%)*	*0 (0%)*
- Influenza A/H3, n(%)	*7 (6%)*	*7 (7%)*	*3 (5%)*	*3 (6%)*	*3 (6%)*	*1 (3%)*
- Influenza B, n(%)	*8 (7%)*	*7 (7%)*	*4 (7%)*	*4 (9%)*	*4 (9%)*	*4 (12%)*
Other respiratory infections (nasal swab)						
Any Parainfluenza strain, n(%)	9 (8%)	9 (9%)	6 (11%)	4 (9%)	4 (9%)	3 (9%)
Adenovirus, n(%)	8 (7%)	7 (7%)	4 (7%)	4 (9%)	5 (11%)	3 (9%)
Coronavirus, n(%)	12 (10%)	9 (9%)	3 (5%)	2 (4%)	5 (11%)	1 (3%)
Human Metapneumovirus, n(%)	8 (7%)	8 (8%)	4 (7%)	4 (9%)	5 (11%)	3 (9%)
Rhinovirus/Enterovirus, n(%)	47 (40%)	42 (41%)	21 (38%)	19 (40%)	17 (36%)	11 (32%)
Respiratory Syncytial Virus, n(%)	20 (17%)	19 (18%)	11 (20%)	8 (17%)	8 (17%)	7 (21%)
Bordetella pertussis, n(%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Mycoplasma pneumoniae, n(%)	3 (3%)	2 (2%)	2 (4%)	2 (4%)	2 (4%)	2 (6%)
Chlamydophila pneumoniae, n(%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Medical history, n mean (SD)						
Duration of illness (days)	118 2.7 (1.2)	103 2.7 (1.1)	55 2.8 (1.0)	47 2.8 (1.1)	47 2.7 (1.1)	34 2.9 (1.0)
Duration of fever (days)	116 1.9 (1.2)	101 1.9 (1.2)	54 2.1 (1.4)	46 2.0 (1.4)	46 2.0 (1.3)	33 2.2 (2.4)

[1]Region A: Thames Valley & South Midlands, West Midlands, North Thames, North West London, South London; Region B: West of England, South West Peninsula, Cardiff & Vale University Health Board, Aneurin Bevan University Health Board, Abertawe Bro Morgannwg University Health Board; Region C: Greater Manchester, North East and North Cumbria, North West Coast, Yorkshire & Humber; Region D: Kent Surrey & Sussex, Wessex & Region E: Eastern, East Midlands

TABLE 2 BASELINE CHARACTERISTICS FOR THE PLACEBO GROUP

	Placebo					
	Total (N=114)	**Consented to swabs (N=98)**	**Swabs available at 3 months (N=45)**	**Swabs available at 6 months (N=45)**	**Swabs available at 12 months (N=46)**	**Swabs available at 3 6 and 12 months (N=26)**
Age (months)						
Median (IQR)	40.7 (22.3 to 71.1)	40.4 (21.7 to 71.1)	40.6 (19.4 to 88.0)	40.9 (20.2 to 69.9)	43.0 (22.3 to 88.0)	40.7 (19.4 to 88.0)
Age						
6-23 months, n(%)	33 (29%)	30 (31%)	14 (31%)	16 (36%)	14 (30%)	9 (35%)
≥2 years, n(%)	81 (71.1%)	68 (69%)	31 (69%)	29 (64%)	32 (70%)	17 (65%)
Age category (by EduraCT guidelines)						
Infants (28 days-23 months), n(%)	33 (29%)	30 (31%)	14 (21%)	16 (36%)	14 (30%)	9 (35%)
Children (2-11 years), n(%)	80 (70%)	67 (68%)	31 (69%)	29 (64%)	32 (70%)	17 (65%)
Adolescents (12-17 years), n(%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Gender						
Male, n(%)	65 (57%)	55 (56%)	29 (64%)	28 (62%)	27 (59%)	16 (62%)
Female, n(%)	49 (43%)	43 (44%)	16 (36%)	17 (38%)	19 (41%)	10 (38%)
Region[1]						
A, n(%)	41 (36%)	39 (40%)	18 (40%)	24 (53%)	26 (57%)	16 (62%)
B, n(%)	23 (20%)	17 (17%)	10 (22%)	9 (20%)	8 (17%)	6 (23%)
C, n(%)	21 (18%)	16 (16%)	7 (16%)	6 (13%)	5 (11%)	4 (15%)
D, n(%)	21 (18%)	19 (19%)	6 (13%)	3 (7%)	4 (9%)	0 (0%)
E, n(%)	8 (7%)	7 (7%)	4 (9%)	3 (7%)	3 (7%)	0 (0%)
Current season influenza vaccination						
Yes, n(%)	39 (34%)	32 (33%)	16 (36%)	15 (33%)	18 (39%)	10 (38%)
No, n(%)	71 (62%)	63 (64%)	29 (64%)	20 (67%)	27 (59%)	16 (62%)
Don't know, n(%)	4 (4%)	3 (3%)	0 (0%)	0 (0%)	1 (2%)	0 (0%)
Last year seasonal influenza vaccination						
Yes, n(%)	36 (32%)	33 (34%)	16 (36%)	17 (38%)	18 (39%)	12 (46%)
No, n(%)	58 (51%)	49 (50%)	23 (51%)	23 (51%)	22 (48%)	14 (54%)
Don't know, n(%)	19 (17%)	16 (16%)	6 (13%)	5 (11%)	6 (13%)	0 (0%)
Missing, n(%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Household smoking status						

	Total		Placebo							
	(N=114)		Consented to swabs (N=98)		Swabs available at 3 months (N=45)		Swabs available at 6 months (N=45)		Swabs available at 12 months (N=46)		Swabs available at 3 6 and 12 months (N=26)	
Non-smoking, n(%)	89 (78%)		78 (80%)		33 (73%)		37 (82%)		42 (91%)		24 (92%)	
Smoking, n(%)	24 (21%)		19 (19%)		11 (24%)		8 (18%)		4 (9%)		2 (8%)	
Missing, n(%)	1 (1%)		1 (1%)		1 (2%)		0 (0%)		0 (0%)		0 (0%)	
At risk categories (not mutually exclusive)												
Respiratory, n(%)	85 (75%)		75 (77%)		31 (69%)		33 (73%)		36 (78%)		16 (62%)	
Neurological, n(%)	9 (8%)		6 (6%)		3 (7%)		2 (4%)		2 (4%)		2 (8%)	
Cardiac, n(%)	4 (4%)		2 (2%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)	
Renal, n(%)	0 (0%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)	
Immunodeficiency, n(%)	0 (0%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)	
Other, n(%)	32 (28%)		28 (29%)		16 (36%)		15 (33%)		13 (28%)		11 (42%)	
- Genetic, n(%)	*7 (22%)*		*7 (25%)*		*4 (25%)*		*5 (33%)*		*4 (31%)*		*4 (36%)*	
- Metabolic, n(%)	*5 (16%)*		*4 (14%)*		*2 (13%)*		*2 (13%)*		*2 (15%)*		*2 (18%)*	
- Premature birth, n(%)	*10 (31%)*		*8 (29%)*		*6 (38%)*		*5 (33%)*		*4 (31%)*		*4 (26%)*	
- Previous recurrent or serious respiratory problems, n(%)	*7 (22%)*		*6 (21%)*		*2 (13%)*		*3 (20%)*		*3 (23%)*		*1 (9%)*	
- Other (allergies, etc.)	*3 (9%)*		*3 (11%)*		*2 (13%)*		*0 (0%)*		*0 (0%)*		*0 (0%)*	
Physical examination, n mean (SD)												
Heart rate (beats/ minute)	113	115 (22.8)	97	114 (22.4)	44	111 (19.7)	45	112 (22.9)	46	109 (21.6)	26	112 (19.5)
Respiratory rate (breaths/minute)	113	28 (10.1)	97	28 (10.3)	44	27 (8.4)	45	28 (8.7)	46	27 (8.3)	26	27 (7.9)
Temperature (°C)	113	37 (0.9)	87	37 (0.8)	44	37 (0.7)	44	37 (0.8)	45	37 (0.7)	25	37 (0.8)
Antibiotics prescribed in the 3 months preceding randomisation												
Yes, n(%)	20 (18%)		17 (17%)		7 (16%)		7 (16%)		6 (13%)		4 (15%)	
No, n(%)	91 (80%)		79 (81%)		38 (84%)		38 (84%)		40 (87%)		22 (85%)	
Not known, n(%)	1 (1%)		1 (1%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)	
Missing, n(%)	2 (2%)		1 (1%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)	
Medication taken during current episode:												
Antivirals												
Yes, n(%)	0 (0%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)	
No, n(%)	114 (100%)		98 (100%)		45 (100%)		45 (0%)		46 (0%)		26 (100%)	
Unknown, n(%)	0 (0%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)	
Missing, n(%)	0 (0%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)		0 (0%)	
Antipyretics												

	Total (N=114)	Placebo: Consented to swabs (N=98)	Placebo: Swabs available at 3 months (N=45)	Placebo: Swabs available at 6 months (N=45)	Placebo: Swabs available at 12 months (N=46)	Placebo: Swabs available at 3 6 and 12 months (N=26)
Yes, n(%)	99 (87%)	84 (86%)	38 (84%)	38 (84%)	39 (85%)	21 (81%)
No, n(%)	14 (12%)	13 (13%)	6 (13%)	6 (13%)	6 (13%)	4 (15%)
Unknown, n(%)	1 (1%)	1 (1%)	1 (2%)	1 (2%)	1 (2%)	1 (4%)
Other medications						
Yes, n(%)	59 (52%)	51 (52%)	21 (47%)	21 (47%)	24 (52%)	12 (46%)
No, n(%)	55 (48%)	47 (48%)	24 (53%)	24 (53%)	22 (48%)	14 (54%)
Not known, n(%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Hib vaccination status						
Yes, n(%)	105 (92%)	93 (95%)	44 (98%)	44 (98%)	45 (98%)	25 (96%)
No, n(%)	5 (4%)	2 (2%)	0 (0%)	1 (2%)	0 (0%)	0 (0%)
Not known, n(%)	2 (2%)	2 (2%)	1 (2%)	0 (0%)	1 (2%)	1 (4%)
Missing, n(%)	2 (2%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PCV vaccination received						
Yes, n(%)	103 (90%)	92 (94%)	44 (98%)	44 (98%)	45 (98%)	25 (96%)
No, n(%)	6 (5%)	3 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Not known, n(%)	3 (3%)	2 (2%)	1 (2%)	1 (2%)	1 (2%)	1 (4%)
Missing, (%)	2 (2%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Any acute consultations in the 12 month period before entering the study						
Yes, n(%)	101 (89%)	89 (91%)	40 (89%)	41 (91%)	42 (91%)	23 (88%)
No, n(%)	10 (9%)	7 (7%)	4 (9%)	3 (7%)	3 (7%)	2 (8%)
Not known, n(%)	1 (1%)	1 (1%)	1 (2%)	1 (2%)	1 (2%)	1 (4%)
Missing, n(%)	2 (2%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Total number of acute consultations in the 12 month period before entering the study						
N	88	78	35	36	38	20
Median (IQR)	5.0 (3.0 to 9.0)	5.0 (3.0 to 9.0)	5.0 (3.0 to 8.0)	6.0 (4.0 to 8.5)	6.0 (4.0 to 9.0)	5.5 (4.0 to 8.0)

	Placebo					
	Total (N=114)	**Consented to swabs (N=98)**	**Swabs available at 3 months (N=45)**	**Swabs available at 6 months (N=45)**	**Swabs available at 12 months (N=46)**	**Swabs available at 3 6 and 12 months (N=26)**
Influenza						
Any Influenza strain, n(%)	14 (12%)	10 (10%)	5 (11%)	5 (11%)	6 (13%)	4 (15%)
- Influenza A, n(%)	*1 (1%)*	*0 (0%)*	*0 (0%)*	*0 (0%)*	*0 (0%)*	*0 (0%)*
- Influenza A/H1, n(%)	*0 (0%)*	*0 (0%)*	*0 (0%)*	*0 (0%)*	*0 (0%)*	*0 (0%)*
- Influenza A/H1-2009, n(%)	*3 (3%)*	*3 (3%)*	*2 (4%)*	*1 (2%)*	*2 (4%)*	*1 (4%)*
- Influenza A/H3, n(%)	*5 (4%)*	*4 (4%)*	*2 (4%)*	*3 (7%)*	*3 (7%)*	*2 (8%)*
- Influenza B, n(%)	*5 (4%)*	*3 (3%)*	*1 (2%)*	*1 (2%)*	*1 (2%)*	*1 (4%)*
Other respiratory infections (nasal swab)						
Any Parainfluenza strain, n(%)	11 (10%)	10 (10%)	3 (7%)	5 (11%)	10 (11%)	3 (12%)
Adenovirus, n(%)	12 (11%)	10 (10%)	5 (11%)	2 (4%)	3 (7%)	1 (4%)
Coronavirus, n(%)	10 (9%)	8 (8%)	5 (11%)	7 (16%)	5 (11%)	3 (12%)
Human Metapneumovirus, n(%)	8 (7%)	8 (8%)	2 (4%)	3 (7%)	4 (9%)	2 (8%)
Rhinovirus/Enterovirus, n(%)	58 (51%)	48 (49%)	24 (53%)	18 (40%)	19 (41%)	11 (42%)
Respiratory Syncytial Virus, n(%)	18 (16%)	17 (17%)	6 (13%)	5 (11%)	4 (9%)	2 (8%)
Bordetella pertussis, n(%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Mycoplasma pneumoniae, n(%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Chlamydophila pneumoniae, n(%)	2 (2%)	1 (1%)	1 (2%)	1 (2%)	1 (2%)	1 (4%)
Medical history, n mean (SD)						
Duration of illness (days)	114 2.7 (1.2)	98 2.7 (1.2)	45 2.7 (1.2)	45 2.8 (1.2)	46 2.7 (1.3)	26 2.9 (1.3)
Duration of fever (days)	112 2.2 (1.1)	96 2.2 (1.1)	43 2.2 (1.2)	43 2.2 (1.2)	44 2.1 (1.2)	24 2.2 (1.3)

[1]Region A: Thames Valley & South Midlands, West Midlands, North Thames, North West London, South London; Region B: West of England, South West Peninsula, Cardiff & Vale University Health Board, Aneurin Bevan University Health Board, Abertawe Bro Morgannwg University Health Board; Region C: Greater Manchester, North East and North Cumbria, North West Coast, Yorkshire & Humber; Region D: Kent Surrey & Sussex, Wessex & Region E: Eastern, East Midlands

Table 3. Participant penicillin prescriptions in GP health records

	3 Months Prior to the Study		During Follow-up Period	
	Co-Amoxiclav (N=118)	Placebo (N=114)	Co-Amoxiclav (N=118)	Placebo (N=114)
PENICILLIN				
Any Penicillin				
Yes, n(%)	22 (18.6%)	18 (15.8%)	2 (1.7%)	8 (7.0%)
N, Mean (sd) duration (days)	16, 6.4 (2.3)	10, 6.2 (2.8)	2, 14.0 (0.0)	8, 7 (4.1)
Missing duration	*6*	*8*	*0*	*0*
Amoxicillin				
Yes, n(%)	19 (16.1%)	14 (12.3%)	1 (0.9%)	7 (6.1%)
N, Mean (sd) duration (days)	14, 6.6 (2.3)	7, 6.4 (3.4)	1, 7.0 (-)	7, 7.3 (4.4)
Missing duration	*5*	*7*	*0*	*0*
Ampicillin				
Yes, n(%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
N, Mean (sd) duration (days)	0, -	0, -	0, -	0, -
Missing duration	-	-	-	-
Penicillin V				
Yes, n(%)	1 (0.9%)	3 (2.6%)	1 (0.9%)	0 (0.0%)
N, Mean (sd) duration (days)	0, -	1, 7.0 (-)	1, 7.0 (-)	0, -
Missing duration	*1*	*2*	*0*	-
Other Penicillin*				
Yes, n(%)	5 (4.2%)	2 (1.8%)	1 (0.9%)	1 (0.9%)
N, Mean (sd) duration (days)	2, 5.0 (0.0)	2, 5.0 (0.0)	1, 14.0 (-)	1, 5.0 (-)
Missing duration	*3*	*0*	*0*	*0*

*3 months prior to the study: Chloramphenicol n=1 (co-amoxiclav n=0, placebo n=1), Flucloxacillin n=4 (co-amoxiclav n=3, placebo n=1), Phenoxymethylpenicillin n=1 (co-amoxiclav n=1, placebo n=0), Tazocin n=1 (co-amoxiclav n=1, placebo n=0). During follow-up period: Flucloxacillin n=2 (co-amoxiclav n=1, placebo n=1).

Table 4. Participant Penicillin/Beta-Lactamase Inhibitor prescriptions in GP health records

	3 Months Prior to the Study		During Follow-up Period	
	Co-Amoxiclav (N=118)	Placebo (N=114)	Co-Amoxiclav (N=118)	Placebo (N=114)
PENICILLIN/BETA-LACTAMASE INHIBITOR				
Any Penicillin/Beta-Lactamase Inhibitor				
Yes, n(%)	4 (3.4%)	0 (0.0%)	2 (1.7%)	0 (0.0%)
N, Mean (sd) duration (days)	4, 10.5 (4.0)	0, -	2, 12.0 (2.8)	0, -
Missing duration	*0*	-	*0*	-
Co-amoxiclav				
Yes, n(%)	4 (3.4%)	0 (0.0%)	2 (1.7%)	0 (0.0%)
N, Mean (sd) duration (days)	4, 10.5 (4.0)	0, -	2, 12.0 (2.8)	0, -
Missing duration	*0*	-	*0*	-
Other Penicillin/Beta-Lactamase Inhibitor				
Yes, n(%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
N, Mean (sd) duration (days)	0, -	0, -	0, -	0, -
Missing duration	-	-	-	-

Table 5. Participant Cephalosporin Inhibitor prescriptions in GP health records

	3 Months Prior to the Study		During Follow-up Period	
	Co-Amoxiclav (N=118)	Placebo (N=114)	Co-Amoxiclav (N=118)	Placebo (N=114)
CEPHALOSPORIN				
Any Cephalosporin				
Yes, n(%)	1 (0.9%)	0 (0.0%)	1 (0.9%)	0 (0.0%)
N, Mean (sd) duration (days)	0, -	0, -	1, 7.0 (-)	0, -
Missing duration	*1*	-	*0*	-
Cefalexin				
Yes, n(%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
N, Mean (sd) duration (days)	0, -	0, -	0, -	0, -
Missing duration	-	-	-	-
Cefradine				
Yes, n(%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
N, Mean (sd) duration (days)	0, -	0, -	0, -	0, -
Missing duration	-	-	-	-
Other Cephalosporin*				
Yes, n(%)	1 (0.9%)	0 (0.0%)	1 (0.9%)	0 (0.0%)
N, Mean (sd) duration (days)	0, -	0, -	1, 7.0 (-)	0, -
Missing duration	*1*	-	*0*	-

*3 months prior to the study: Ceftriaxone n=1 (co-amoxiclav n=1, placebo n=0). During follow-up period: Ceftriaxone n=1 (co-amoxiclav n=1, placebo n=0)